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17q21 variant increases the risk of exacerbations in asthmatic
children despite inhaled corticosteroids use
To the Editor,
Approximately 25% of the asthmatic children suffer from uncon-
trolled asthma despite regular use of inhaled corticosteroids (ICS).1
Variation within the 17q21 locus is the strongest genetic determi-
nant for childhood-onset asthma.2 Recently, the influence of this
locus on treatment outcomes has been shown in several studies.3-4
The Pharmacogenomics in Childhood Asthma (PiCA) consortium is a
multiethnic consortium that brings together data from ≥14 000 asth-
matic children/young adults from 12 different countries to study the
pharmacogenomics of uncontrolled asthma despite treatment.5 In 14
PiCA populations (with over 4000 asthmatic patients), we studied
the association between variation in the 17q21 locus, and asthma
exacerbations despite ICS use. We specifically focused on
rs7216389, a single nucleotide polymorphism (SNP) in the 17q21
locus strongly associated with childhood asthma and initially identi-
fied by Moffatt et al.2
Ten PiCA studies included patients with non-Hispanic European
origins, two included Hispanic patients, one African American, and
one included East Asian patients. Additional details of the study pop-
ulations can be found in the Data S1. Two outcomes were assessed:
(i) asthma-related hospitalizations/emergency department visit (ED)
visits and (ii) short courses of oral corticosteroid (OCS) use reported
by the parent/child at the study visit or based on completed study
questionnaires. Age, gender, genotype data, and exacerbation data
were available for 4529 steroid-treated children and young adults
(Table 1). Logistic regression analysis was used to assess the risk of
exacerbations when carrying rs7216389. Due to potential hetero-
geneity between cohorts, the odds ratios (ORs) were meta-analyzed
with the inverse variance weighting method assuming random
effects. See Data S1 for more detail.
The risk allele (T) frequency was highest in East Asians (n = 182,
T = 0.81), followed with African Americans (T = 0.79, n = 468) and
Hispanics (T = 0.66, total n = 916), and it was less frequent in
patients with European ancestry (ranged between 0.54 and 0.62,
total n = 2963). The genotype distribution of the SNP was in Hardy-
Weinberg equilibrium in all cohorts. There was a low to moderate
heterogeneity between studies (Figure 1). Exacerbation rates ranged
between 6.5% (PACMAN) and 77.2% (HPR) for OCS use and 6%
(PACMAN) and 58% (GALA II and HPR) for hospitalizations/ED
visits.
Thirty percent (1378 out of 4454) of the patients reported hos-
pitalizations/ED visits. In the meta-analysis of 13 studies, rs7216389
was statistically significantly associated with asthma-related ED vis-
its/hospitalizations, (summary OR per increase in risk allele: 1.32,
95% CI: 1.17- 1.49, P < .0001, I2 = 3.9%) (Figure 1A). In a subgroup
analysis, the effect estimates for hospitalizations/ED visits were
approximately the same for both non-Hispanic whites (n = 2888,
OR: 1.33, 95% CI: 1.10-1.61, P = .004, I2 = 30.2%) and Hispanics
(n = 916, OR: 1.31, 95% CI: 1.06-1.63, P = .01, I2 = 0.00%). Thirty-
one percent (1269 out of 4050) of the patients reported OCS use/
high-dose ICS. In the meta-analysis of the nine studies, the
rs7216389-T was statistically significantly associated with an
increased risk of OCS use/high-dose ICS (summary OR per increase
in variant allele: 1.19, 95% CI: 1.04-1.36, P = .01, I2 = 22.8%) (Fig-
ure 1B). Rs7216389 was associated with OCS use in the meta-analy-
sis of seven European studies (n = 2492, OR: 1.26, 95% CI: 1.09-
1.45, P = .002, I2 = 6.2%) but not in Hispanics (n = 916, OR: 0.96,
95% CI: 0.76-1.22, P = .7, I2 = 0.00%). Differences in the minor
allele frequencies and LD structures among different ethnicities can
influence results of the association studies.6 This could be one of
the potential explanations why we did not find a significant associa-
tion in African Americans and patients from Singapore.
A sensitivity analysis was performed to investigate this associa-
tion in children ≥5 years of age. When excluding children <5 years
of age in the meta-analysis, the results remained significant. In the
meta-analysis of 13 studies, the SNP was associated with asthma-
related hospitalization/ED visits (n = 4254, OR: 1.32, 95% CI: 1.18-
1.49, P < .0001, I2 = 0.0%) (Figure S1). Regarding OCS use, 10 stud-
ies collected data on patients ≥5 years of age (n = 3771). In the
meta-analysis of 10 studies, rs7216389 was associated with the
OCS use (summary OR: 1.20, 95% CI: 1.05-1.38, P = .01,
I2 = 21.7%) (Figure S2).
We also performed a meta-analysis of the studies that had suffi-
cient data available on preschool children (2-4 years of age).
Although the effect estimates in younger children were in the same
direction for both outcomes, the results were not statistically
significant (Figures S3 & S4). All preschool studies solely included
European children.
Altered expression of ORMDL3 and GSDMB by 17q21 locus
variants may play a key role in childhood asthma onset.2,7 Two
17q21 asthma-risk variants (rs4065275 and rs12936231) in high
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Figure 1. Forest Plots of rs7216389 for (A) asthma-related hospitalizations/ED visits in thirteen studies and (B) OCS/high-dose ICS use in
eleven studies. Odds Ratios (OR) and corresponding 95% Confidence Intervals (95% CI) for individuals with rs7216389, controlling for age,
gender, and BTS treatment step [Colour figure can be viewed at wileyonlinelibrary.com]
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linkage disequilibrium (LD) with rs7216389 were reported to
switch CTCF-binding sites that resulted in increased expression of
ORMDL3 in CD4+ T cells which subsequently reduced interleukin-
2 production.8
Rs7216389 has previously shown to be associated with exacer-
bations3 and poor lung function in Caucasian children using ICS.4
Even though in our study Caucasians were the largest group, this
study is the largest multiethnic population evaluating the association
between 17q21 variant and asthma exacerbations in ICS users.
Rs7216389 seems to increase bronchial responsiveness and there-
fore exacerbation rates in children,9 suggesting that carriers of
rs7216389 might have a more severe form of asthma. However, by
adding British Thoracic Society (BTS) treatment steps as a marker of
disease severity to the model, we argue that the association reflects,
at least partly, poor response to ICS.
Limitations of the study include the use of retrospective report-
ing of exacerbations in the observational cohort studies. However,
the effect was also observed in a clinical trial population (CAMP),
where exacerbations were reported prospectively. Hence, we do not
believe that using retrospective data has significantly influenced the
results. As not all studies had data available on both hospitaliza-
tions/ED visits and OCS use, we did not combine the two outcomes
in our analysis. Furthermore, as information on treatment adherence
was not available in all included studies, it was not considered in the
analysis.
We show that 17q21, a widely replicated asthma susceptibility
locus, is also associated with an increased risk of exacerbations in
children/young adults treated with ICS. A better understanding of
the molecular mechanisms underlying exacerbation-prone phenotype
of pediatric asthma could lead to a better classification of different
pediatric asthma phenotypes and the identification of novel treat-
ment targets.
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Association of mast cells with clinical, endoscopic, and
histologic findings in adults with eosinophilic esophagitis
To the Editor,
Eosinophilic esophagitis (EoE) presents with diverse features which
can differ between children and adults, as well as among adults,
but eosinophils alone do not account for this heterogeneity.1,2
Mast cells are involved in EoE pathogenesis, are highly increased
in EoE compared to non-EoE controls, and mast cell-associated
genes are upregulated in EoE.2-5 Mast cells also produce the profi-
brotic factor TGF-b1 and promote smooth muscle contraction.6
However, the extent to which mast cell presence correlates with
clinical features of EoE is unknown. We aimed to determine
whether esophageal mast cell levels correlated with clinical symp-
toms, endoscopic findings, and histologic features in newly diag-
nosed adults with EoE.
We performed a secondary analysis of data and biospecimens
collected during a prospective cohort study of EoE cases, details of
which have been previously described.7 The parent study included
adults (>18) undergoing outpatient endoscopy for symptoms of eso-
phageal dysfunction. EoE was diagnosed by consensus guidelines.8
TABLE 1 Patient characteristic, and characteristics stratified by the highest and lowest mast cell quartile, and by mast cell to eosinophil
ratios ≤1 and >1
Characteristic
Overall EoE
population
(n = 96)
Lowest mast cell
quartile (n = 24)
Highest mast cell
quartile (n = 24) P
Mast cell to eos
ratio ≤ 1 (n = 72)
Mast cell to eos
ratio > 1 (n = 24) P
Mast cell density
(mean cells/
mm2  SD)
266.8  180.0 88.7  32.6 515.3  157.4 - 235.1  142.2 361.6  242.6 0.002
Eosinophil density
(eos/mm2;
mean  SD)
555.9  478.1 304.2  212.0 717.5  501.1 <0.001 664.6  498.8 229.8  168.8 <0.001
Age at diagnosis
(mean  SD)
37.2  12.7 38.0  14.2 38.4  13.6 0.91 37.1  12.6 37.6  13.2 0.88
Male (n, %) 54 (56) 10 (42) 15 (63) 0.15 38 (53) 16 (67) 0.24
White (n, %) 91 (95) 23 (96) 24 (100) 0.31 68 (94) 23 (96) 0.79
Symptoms
Dysphagia (n, %) 94 (98) 24 (100) 23 (96) 0.31 71 (99) 23 (96) 0.41
>5 y of dysphagia
(n, %)
53 (60) 13 (56) 12 (55) 0.51 37 (57) 16 (70) 0.67
VASa score
(mean  SD
3.5  2.7 2.4  1.9 3.6  2.8 0.12 3.5  2.6 3.5  3.0 0.97
Heartburn (n, %) 8 (8) 1 (4) 2 (8) 0.55 7 (10) 1 (4) 0.39
(Continues)
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